Edition:
United Kingdom

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

2.34USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$2.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
41,141
52-wk High
$16.85
52-wk Low
$1.98

Chart for

About

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme,... (more)

Overall

Beta: --
Market Cap(Mil.): $332.96
Shares Outstanding(Mil.): 23.46
Dividend: --
Yield (%): --

Financials

  AQXP.OQ Industry Sector
P/E (TTM): -- 31.13 33.63
EPS (TTM): -1.88 -- --
ROI: -38.16 15.55 15.02
ROE: -38.28 16.92 16.60

Aquinox to stop development of lead drug; shares plunge

Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent.

27 Jun 2018

UPDATE 2-Aquinox to stop development of lead drug; shares plunge

June 27 Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent.

27 Jun 2018

Aquinox Pharma's bladder pain drug fails to meet study goal

June 27 Aquinox Pharmaceuticals Inc said on Wednesday its treatment for bladder pain syndrome failed to meet the main goal of a late-stage trial, and the company plans to stop developing the drug.

27 Jun 2018

Earnings vs. Estimates